Unique collection development tool featuring the most extensive database of expert reviews of books, eBooks, and software in the health sciences, now with over 44,000 reviews.
Bibliographic information on over 210,000 book, eBook, and software titles in 120 specialties.
Weekly email reporting on new reviews and new titles in your areas of interest.
Discover e-versions of books available from your favorite aggregators!
Click here for a complete listing.
Includes Doody's Core Titles 2024
Annual subscription allows up to 5 users at your institution to sign up for their own weekly updates.
Quick and Advanced search engines; List Manager to create, store, share and e-mail lists of titles.
Manage your subscription online: add/delete users; print invoices and submit payments.
eBook/Digital Version available from:
Web Site

AHFS Drug Information 2024
Doody's Core Title (2024 Edition)
Score(s): 2.6 (Health Sciences - Pharmacy)
Essential Purchase Title
ISBN: 978-1-58528-721-5, 3504 pages, Soft Cover
ISBN-10: 1-58528-721-0
Copyright: 2024
Edition: 1st
Author: ASHP
Specialties: Pharmacy
Publisher: ASHP
4500 East West Highway
Bethesda, MD 20814
P: 866-279-0681
List Price: $491.00
Checking for Limited Preview at Google
View Large Size

View Citation Citation

At A Glance

Discover the most comprehensive and reliable drug information source with AHFS Drug Information? 2024, a trusted choice on the Doody's Core Titles List from 2020 to 2023. This essential reference is your all-in-one solution for evidence-based therapeutic guidelines and off-label uses, ensuring you have the information you need to protect your patients and enhance your practice.

The 2024 edition is thoroughly updated and expanded, featuring over 97,000 references and insights from leading experts. Stay ahead with the latest clinical perspectives, including therapy placement discussions and guideline recommendations. Dive into in-depth coverage of specialty medications for complex, chronic conditions that demand precise handling, monitoring, and dosage adjustments.

Explore contemporary topics such as new treatments and vaccines for RSV, safety considerations for GLP-1 agonists, novel orphan drugs, and biosimilars. Gain knowledge on emerging gene therapies and updated vaccine monographs, including pneumococcal, rabies, and RSV vaccines.

AHFS DI 2024 also provides crucial information on off-label uses, long-term clinical data, MedWatch alerts, Standardize4Safety initiatives, REMS data, and targeted FDA updates. Additionally, it introduces content on over 175 new molecular entities and therapeutic biological products, with significant revisions on nearly 190 medications.

Learn more and order here.